Product NDC: | 55289-525 |
Proprietary Name: | ERY-TAB |
Non Proprietary Name: | Erythromycin |
Active Ingredient(s): | 333 mg/1 & nbsp; Erythromycin |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET, DELAYED RELEASE |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 55289-525 |
Labeler Name: | PD-Rx Pharmaceuticals, Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA062298 |
Marketing Category: | ANDA |
Start Marketing Date: | 20110418 |
Package NDC: | 55289-525-42 |
Package Description: | 42 TABLET, DELAYED RELEASE in 1 BOTTLE, PLASTIC (55289-525-42) |
NDC Code | 55289-525-42 |
Proprietary Name | ERY-TAB |
Package Description | 42 TABLET, DELAYED RELEASE in 1 BOTTLE, PLASTIC (55289-525-42) |
Product NDC | 55289-525 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Erythromycin |
Dosage Form Name | TABLET, DELAYED RELEASE |
Route Name | ORAL |
Start Marketing Date | 20110418 |
Marketing Category Name | ANDA |
Labeler Name | PD-Rx Pharmaceuticals, Inc. |
Substance Name | ERYTHROMYCIN |
Strength Number | 333 |
Strength Unit | mg/1 |
Pharmaceutical Classes | Decreased Sebaceous Gland Activity [PE],Macrolide [EPC],Macrolide Antimicrobial [EPC],Macrolides [Chemical/Ingredient] |